Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open 2017;2:e000185.Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2(2): e000185....
Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.doi:10.1038/ncpuro0262Tamsin Osborne TNature Clinical Practice Urology...
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKAbstract: With the increasing understanding of the biology of the disease and the development of targeted therapy, there has been a paradigm shift in the treatment of clear cell metastatic renal cell carcinoma (...
L. et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542–4549 (2007). CAS PubMed Google Scholar Larkin, J. M. et al. A phase I/II trial of sorafenib and ...
带着这样的疑问,美国得克萨斯大学 MD 安德森癌症中心的研究人员展开了深入研究,并将研究成果发表在《Nature Communications》期刊上,论文题目是 “Combined immune checkpoint therapy and cytoreductive surgery in metastatic clear cell renal cell carcinoma: a prospective pilot trial”。他们发现,ICT 与减瘤手术联合治...
Serum Levels of Vascular Endothelial Growth Factor (VEGF) and Endostatin in Renal Cell Carcinoma Patients Compared to a Control Group Renal cell carcinoma (RCC) is a vascularised neoplasm. The importance of the angiogenic process in its growth and metastatic spreading is widely recognised... L S...
from patients with acute lymphoblastic leukemia are actually composed of multiple families of genetically distinct leukemia cells [35]. No doubt, that the treatment of such a diverse pathology would not be efficient without understanding of the most general regulatory mechanisms common for all canc...
The efficacy and safety of mTOR inhibitors has been demonstrated in different tumors, including lymphomas, breast and renal cell carcinomas (RCC) [57,58]. A robust antitumor activity of everolimus has also been consistently demonstrated in the phase II/III RADIANT trials across a broad spectrum ...
在肾癌(Renal Cell Carcinoma,RCC)领域,也有不少关于假包膜的研究。比如,Kawakami 等人发现,使用阿昔替尼进行新辅助治疗后,肾癌患者的假包膜厚度明显增加,而肾脏的一些其他结构,像肾小球硬化、动脉硬化和肾硬化的程度却没有改变,这表明假包膜能在相对较短的时间内 “重新发育”。2009 年,Minervini 等人报告了 90 ...
in which autologous γδT cells infused in combination with IL-2 into ten patients with metastatic renal cell carcinoma (mRCC), have proved the safety and efficacy of γδT cells in the clinical setting [102]. These unique characteristics have prompted researchers to use γδT cells for CAR...